Image Credit: STAT News

STAT+: GSK to buy cancer-focused IDRx in $1 billion deal

Watchdoq January 13, 2025

Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront.